Advancements in the clinical management of upper tract urothelial carcinoma

被引：8

作者：

Taylor, Jacob ^{[1
]}

Meng, Xiaosong ^{[2
]}

Ghandour, Rashed ^{[2
]}

Margulis, Vitaly ^{[2
,3
]}

机构：

[1] NYU Langone Hlth, Dept Urol, New York, NY USA

[2] UT Southwestern Med Ctr, Dept Urol, Dallas, TX 75390 USA

[3] Sechenov Univ, Inst Urol & Reprod Hlth, Moscow, Russia

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2019年 / 19卷 / 12期

关键词：

Upper tract urothelial carcinoma; urologic advances; cancer care; neoadjuvant chemotherapy; immunotherapy; UPPER URINARY-TRACT; EARLY INTRAVESICAL INSTILLATION; SUSTAINED-RELEASE FORMULATION; CISPLATIN-INELIGIBLE PATIENTS; TRANSITIONAL-CELL CARCINOMA; INVASIVE BLADDER-CANCER; RADICAL NEPHROURETERECTOMY; NEOADJUVANT CHEMOTHERAPY; ONCOLOGIC OUTCOMES; LYNCH SYNDROME;

D O I：

10.1080/14737140.2019.1698295

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: Upper tract urothelial carcinoma (UTUC) remains a complex disease to manage given challenges in staging, surgical resection, use of perioperative therapy, and prevention of bladder recurrences. High-level evidence is limited to guide management; however, recent data have shifted treatment paradigms. We intend to review recent evidence on advancements in the clinical management for UTUC. Areas covered: This review summarizes advancements in pre-operative work-up, surgical technique, and the use of intravesical and systemic therapy in both the neoadjuvant and adjuvant settings. Special comment is made on progress in the genomics of UTUC and how that can inform clinical practice. Expert opinion: Advancements in the clinical management of UTUC are most prominently being made in the neoadjuvant chemotherapy setting. Although level I evidence is sparse, data from both single and multi-institutional retrospective studies strongly encourage the use of neoadjuvant chemotherapy especially in high-risk or advanced-stage patients.

引用

页码：1051 / 1060

页数：10

共 134 条

[1] Performance of diffusion-weighted MRI post-CT urography for the diagnosis of upper tract urothelial carcinoma: Comparison with selective urine cytology sampling [J].

Akita, Hirotaka ;

Kikuchi, Eiji ;

Hayakawa, Nozomi ;

Mikami, Shuji ;

Sugiura, Hiroaki ;

Oya, Mototsugu ;

Jinzaki, Masahiro .

CLINICAL IMAGING, 2018, 52 :208-215

[2] Microsatellite instability in urothelial carcinoma of the upper urinary tract [J].

Amira, N ;

Rivet, J ;

Soliman, H ;

Cancel-Tassin, G ;

Le Duc, A ;

Janin, A ;

Cussenot, O .

JOURNAL OF UROLOGY, 2003, 170 (04) :1151-1154

[3]

[Anonymous], 2005, EUR UROL, V48, P202

[4] Avelumab treatment for metastatic urothelial carcinoma in the phase Ib JAVELIN Solid Tumor Study: Updated safety and efficacy analysis with ≥ two years of follow-up. [J].

Apolo, Andrea B. ;

Ellerton, John Allan ;

Infante, Jeffrey R. ;

Agrawal, Manish ;

Gordon, Michael S. ;

Aljumaily, Raid ;

Britten, Carolyn D. ;

Dirix, Luc ;

Lee, Keun-Wook ;

Taylor, Matthew H. ;

Schoffski, Patrick ;

Wang, Ding ;

Ravaud, Alain ;

Xiong, Junyuan ;

Rosen, Galit ;

Gulley, James L. ;

Patel, Manish R. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)

[5] Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study [J].

Apolo, Andrea B. ;

Infante, Jeffrey R. ;

Balmanoukian, Ani ;

Patel, Manish R. ;

Wang, Ding ;

Kelly, Karen ;

Mega, Anthony E. ;

Britten, Carolyn D. ;

Ravaud, Alain ;

Mita, Alain C. ;

Safran, Howard ;

Stinchcombe, Thomas E. ;

Srdanov, Marko ;

Gelb, Arnold B. ;

Schlichting, Michael ;

Chin, Kevin ;

Gulley, James L. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2117-+

[6] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].

Balar, Arjun V. ;

Castellano, Daniel ;

O'Donnell, Peter H. ;

Grivas, Petros ;

Vuky, Jacqueline ;

Powles, Thomas ;

Plimack, Elizabeth R. ;

Hahn, Noah M. ;

de Wit, Ronald ;

Pang, Lei ;

Savage, Mary J. ;

Perini, Rodolfo F. ;

Keefe, Stephen M. ;

Bajorin, Dean ;

Bellmunt, Joaquim .

LANCET ONCOLOGY, 2017, 18 (11) :1483-1492

[7] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[8] Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1. [J].

Balar, Arjun Vasant ;

Galsky, Matt D. ;

Loriot, Yohann ;

Dawson, Nancy Ann ;

Necchi, Andrea ;

Srinivas, Sandy ;

Joseph, Richard Wayne ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Drakaki, Alexandra ;

Duran, Ignacio ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Hoffman-Censits, Jean H. ;

Cui, Na ;

Mariathasan, Sanjeev ;

Thastrom, Ann Christine ;

Abidoye, Oyewale O. ;

Bajorin, Dean F. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)

[9] Drug-eluting biodegradable ureteral stent: New approach for urothelial tumors of upper urinary tract cancer [J].

Barros, Alexandre A. ;

Browne, Shane ;

Oliveira, Carlos ;

Lima, Estevao ;

Duarte, Ana Rita C. ;

Healy, Kevin E. ;

Reis, Rui L. .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 513 (1-2) :227-237

[10] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].

Bellmunt, J. ;

de Wit, R. ;

Vaughn, D. J. ;

Fradet, Y. ;

Lee, J. -L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D. I. ;

Culine, S. ;

Sternberg, C. N. ;

Mai, Y. ;

Poehlein, C. H. ;

Perini, R. F. ;

Bajorin, D. F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026

← 1 2 3 4 5 6 7 8 9 10 →